FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4240467833> ?p ?o ?g. }

• W4240467833 endingPage "4197" @default.
• W4240467833 startingPage "4197" @default.
• W4240467833 abstract "4197 Background: The prognosis of advanced biliary tract cancer (ABTC) is very poor. Common systemic chemotherapy (CHT) have been reported to produce transient partial remission only in a small proportion of patients (PTS). Aim of this study is to evaluate the effectiveness of regional CHT combined with systemic CHT in PTS with ABTC. Methods: From January 2000 to May 2003, we treated 26 PTS with the combination of intra-arterial CHT (epirubicin 50 mg/sqm and cisplatin 60 mg/sqm, infused bolus by angiographic catheter introduced in proper hepatic artery, with Seldinger technique, on day 1) and e.v. continuous infusion of 5-FU 200 mg/sqm/day, from day 1 to day 14. Cycles were repeated every 3 weeks. 13 PTS were male; median age was 65 years (49–75); performance status was 0–1 in 17 PTS, 2 in 9 PTS; all had hystological confirmed ABTC; 21 PTS had cholangiocarcinoma and 5 PTS had gallbladder carcinoma, with liver involvement > 50% in 10 and < 50% in 16 PTS; three PTS ha peritoneal involvement, 3 had pleural metastases and 2 had bone involvement. Results: 125 cycles were administered, with a median of 6 cycles per patient (1–8); no side effects related to angiographic procedure were observed, while 6 cases of deep venous thrombosis related to central venous catheter occurred. We observed a case of acute pancreatitis and a case of transitory bowel occlusion. Moreover 1 grade III leukopenia, 2 grade III mucositis and 4 grade III alopecia occurred. The overall response rate, including complete response (CR), partial response (PR) and stable disease (SD) was 21/26 (80%); 1 patient had CR, evaluated by positron emission tomography (PET), 8 PTS had PR, 12 had SD and 5 showed a progression of disease. The Ca 19–9 level decreased more than 50% in 11 out of 16 PTS with abnormal baseline level (68%). After a median follow up of 20.5 months (4–47), median survival is 11 months and 1–2 year survival is 42% and 11%, respectively. Median time to progression is 7 months (3–19). Conclusions: This combined regimen appears feasible and safety and shows an interesting response rate and survival in PTS with ABTC. No significant financial relationships to disclose." @default.
• W4240467833 created "2022-05-12" @default.
• W4240467833 creator A5017906533 @default.
• W4240467833 creator A5018226027 @default.
• W4240467833 creator A5018951199 @default.
• W4240467833 creator A5024290786 @default.
• W4240467833 creator A5029806290 @default.
• W4240467833 creator A5043872623 @default.
• W4240467833 creator A5051447048 @default.
• W4240467833 creator A5060772323 @default.
• W4240467833 creator A5075853129 @default.
• W4240467833 creator A5081700550 @default.
• W4240467833 date "2004-07-15" @default.
• W4240467833 modified "2023-09-26" @default.
• W4240467833 title "Intra-arterial hepatic chemotherapy combined with systemic infusion of 5-FU in patients with advanced biliary tract cancers" @default.
• W4240467833 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.4197" @default.
• W4240467833 hasPublicationYear "2004" @default.
• W4240467833 type Work @default.
• W4240467833 citedByCount "2" @default.
• W4240467833 crossrefType "journal-article" @default.
• W4240467833 hasAuthorship W4240467833A5017906533 @default.
• W4240467833 hasAuthorship W4240467833A5018226027 @default.
• W4240467833 hasAuthorship W4240467833A5018951199 @default.
• W4240467833 hasAuthorship W4240467833A5024290786 @default.
• W4240467833 hasAuthorship W4240467833A5029806290 @default.
• W4240467833 hasAuthorship W4240467833A5043872623 @default.
• W4240467833 hasAuthorship W4240467833A5051447048 @default.
• W4240467833 hasAuthorship W4240467833A5060772323 @default.
• W4240467833 hasAuthorship W4240467833A5075853129 @default.
• W4240467833 hasAuthorship W4240467833A5081700550 @default.
• W4240467833 hasConcept C126322002 @default.
• W4240467833 hasConcept C141071460 @default.
• W4240467833 hasConcept C2776694085 @default.
• W4240467833 hasConcept C2776755627 @default.
• W4240467833 hasConcept C2777063308 @default.
• W4240467833 hasConcept C2780835546 @default.
• W4240467833 hasConcept C2780873365 @default.
• W4240467833 hasConcept C2909463153 @default.
• W4240467833 hasConcept C43376680 @default.
• W4240467833 hasConcept C71924100 @default.
• W4240467833 hasConcept C90924648 @default.
• W4240467833 hasConceptScore W4240467833C126322002 @default.
• W4240467833 hasConceptScore W4240467833C141071460 @default.
• W4240467833 hasConceptScore W4240467833C2776694085 @default.
• W4240467833 hasConceptScore W4240467833C2776755627 @default.
• W4240467833 hasConceptScore W4240467833C2777063308 @default.
• W4240467833 hasConceptScore W4240467833C2780835546 @default.
• W4240467833 hasConceptScore W4240467833C2780873365 @default.
• W4240467833 hasConceptScore W4240467833C2909463153 @default.
• W4240467833 hasConceptScore W4240467833C43376680 @default.
• W4240467833 hasConceptScore W4240467833C71924100 @default.
• W4240467833 hasConceptScore W4240467833C90924648 @default.
• W4240467833 hasIssue "14_suppl" @default.
• W4240467833 hasLocation W42404678331 @default.
• W4240467833 hasOpenAccess W4240467833 @default.
• W4240467833 hasPrimaryLocation W42404678331 @default.
• W4240467833 hasRelatedWork W1999706042 @default.
• W4240467833 hasRelatedWork W2074648981 @default.
• W4240467833 hasRelatedWork W2364106504 @default.
• W4240467833 hasRelatedWork W2378088005 @default.
• W4240467833 hasRelatedWork W2381296894 @default.
• W4240467833 hasRelatedWork W2388488327 @default.
• W4240467833 hasRelatedWork W2406474606 @default.
• W4240467833 hasRelatedWork W2407645462 @default.
• W4240467833 hasRelatedWork W2409812054 @default.
• W4240467833 hasRelatedWork W2895525386 @default.
• W4240467833 hasVolume "22" @default.
• W4240467833 isParatext "false" @default.
• W4240467833 isRetracted "false" @default.
• W4240467833 workType "article" @default.